Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Page 1
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Amato AA, et al. Among authors: badrising ua. Neurology. 2021 Mar 23;96(12):e1595-e1607. doi: 10.1212/WNL.0000000000011626. Epub 2021 Feb 17. Neurology. 2021. PMID: 33597289 Free PMC article. Clinical Trial.
OBJECTIVE: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). ...CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was saf …
OBJECTIVE: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). ...CLASS …
Interventions for dysphagia in long-term, progressive muscle disease.
Jones K, Pitceathly RD, Rose MR, McGowan S, Hill M, Badrising UA, Hughes T. Jones K, et al. Among authors: badrising ua. Cochrane Database Syst Rev. 2016 Feb 9;2(2):CD004303. doi: 10.1002/14651858.CD004303.pub4. Cochrane Database Syst Rev. 2016. PMID: 26859621 Free PMC article. Review.
From our search for RCTs, we identified two other non-randomised studies, which reported the effects of long-term intravenous immunoglobulin therapy in adults with IBM and lip-strengthening exercises in children with myotonic dystrophy type 1. Headaches affected two partic …
From our search for RCTs, we identified two other non-randomised studies, which reported the effects of long-term intravenous immunog …
A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.
Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. Cox FM, et al. Among authors: badrising ua. Brain. 2011 Nov;134(Pt 11):3167-75. doi: 10.1093/brain/awr217. Epub 2011 Sep 9. Brain. 2011. PMID: 21908393
Sporadic inclusion body myositis is considered to be a slowly progressive myopathy. Long-term follow-up data are, however, not yet available. Follow-up data are important with a view to informing patients about their prognosis and selecting appropriate outcome measures for …
Sporadic inclusion body myositis is considered to be a slowly progressive myopathy. Long-term follow-up data are, however, not yet av …
Pain in Guillain-Barre syndrome: a long-term follow-up study.
Ruts L, Drenthen J, Jongen JL, Hop WC, Visser GH, Jacobs BC, van Doorn PA; Dutch GBS Study Group. Ruts L, et al. Neurology. 2010 Oct 19;75(16):1439-47. doi: 10.1212/WNL.0b013e3181f88345. Epub 2010 Sep 22. Neurology. 2010. PMID: 20861454